Advancing precision medicine through next-gen liquid biopsy platform and Infectious Disease testing
02/06/2025
On Day 4 of , visit Predicine at Booth #14095 to discover how our AAA solutions accelerate biomarker discovery, boost trial efficiency, and advance precision oncology.
Today’s featured publication highlight:
• RNA solutions for ADC development
• Comprehensive genomic, transcriptomic, and epigenomic profiling in MIBC
Stop by Predicine Booth #14095 to explore how Predicine’s liquid biopsy platforms deliver comprehensive genomic and epigenomic insights, driving non-invasive, real-time tumor profiling.
Discover how Predicine is advancing precision oncology with 3 featured presentations at ASCO today, highlighting innovative liquid biopsy applications in real-world and clinical trial settings.
• Whole genome methylation profiling in NSCLC
• Liquid biopsy detection of MET amplification in EGFR-mutant NSCLC
• Comprehensive detection of DDR variants in mPDAC
On Day 5 of , visit Predicine at Booth #2643 to see how end-to-end liquid biopsy revolutionizing oncology trials is—from global sample logistics to ultra-sensitive molecular insights.
Highlights
• One-stop Global Sample Management:
PredicineDIRECT™ delivers a “from sample to result” workflow with fast turnaround time, cost-effective management, and accurate specimen tracking by combining worldwide collection, real-time SNP barcoding, and tumor-fraction monitoring.
• Prostate Cancer Detection:
PredicineSCORE™ delivers non-invasive early cancer detection with high sensitivity and accuracy by leveraging AI-driven integration of cfDNA fragmentomic characteristics, including regional coverage, end-motif signatures, and EM-refined copy-number burden.
Stop by Booth #2643 to learn how Predicine’s AAA solutions are accelerating biomarker discovery, enhancing trial efficiency, and advancing precision oncology.
29/04/2025
On day 4 of AACR, Predicine presents 9 posters including Tumor-informed MRD: High concordance between baseline blood- and tissue-informed MRD detection in SCLC using PredicineBEACON™ assay.
• Tumor-naive MRD: Increased sensitivity across bladder, colorectal, and other cancers by combining cfDNA methylation-based MRD detection with fragmentomics.
• Treatment monitoring: Non-invasive response assessment during bladder-sparing therapy through longitudinal plasma and urine ctDNA tumor-fraction tracking.
• Resistance profiling: Enhanced detection of AR drug-driven resistance mutations using Predicine’s cfDNA + cfRNA solutions.
Visit us at Booth #2643 to connect with the Predicine team!
28/04/2025
Booth 2643 at : Empowering Clinical Trials with Liquid Biopsy
Join us at Booth 2643 to explore how Predicine’s AAA solutions are advancing 4 clinical trials with non-invasive precision:
• HR+ Breast Cancer: PredicineCARE™ quantified ctDNA tumor fraction to predict resistance to CDK4/6 inhibitors.
• BRAF-Driven Tumors: PredicineCARE™ tracked BRAF V600E dynamics under plixorafenib, confirming drug response.
• PDL1 Negative NSCLC: PredicineALERT™ methylation profiling guided therapy response monitoring and early decisions.
04/04/2025
Join Us at World CB & CDx London 2025!
Predicine is proud to sponsor the 15th Annual World CB & CDx Summit Europe (April 8–10, London)!
Save the Date:
Dr. Shidong Jia, our CEO, will present groundbreaking MRD solutions for clinical trials on April 10 at 11:40 AM Local Time.
Key highlights include:
🔹 Personalized and actionable MRD via tissue/blood/urine
🔹 Methylation-based MRD without baseline samples
🔹 Validated in trials published in NEJM and Nature Medicine
Meet us at our booth #8 to explore:
PredicineCOMPLETE™: Multi-omics liquid biopsy for precision oncology
PredicineBEACON and PredicineALERT MRD assays
Global partnership support and benefits
Let’s revolutionize precision medicine together!
04/03/2025
March is Colorectal Cancer Awareness Month! 💙
At Predicine, we’re transforming colorectal cancer care with cutting-edge liquid biopsy and tissue-free MRD assays. Early screening saves lives, and Innovative liquid biopsy technology is redefining CRC detection, drug development, and personalized treatment. Better insights, better outcomes.
This month, we encourage you to join us in raising awareness and empowering individuals with knowledge. Talk to your doctor about screening options and join us in the fight against colorectal cancer!
19/02/2025
Meet Predicine at the 9th Liquid Biopsy for Precision Oncology Summit! 📍 Feb 18-20, 2025 | San Diego, CA
Visit Predicine booth to explore how Predicine’s Accurate, Accessible, and Affordable (AAA) liquid biopsy solutions are accelerating biomarker discovery, global clinical trials, CDx development, and commercialization.
Key Highlights:
• Personalized MRD and Methylation-based MRD – Liquid, tissue, and tumor-agnostic approaches for minimal residual disease, recurrence, and molecular response.
• Comprehensive Genomic Profiling – Detecting SNVs, indels, fusions, and CNVs including amplification (HER2 & MET) and deletions (PTEN, BRCA, MTAP) for targeted therapy selection.
• PredicineCOMPLETE – Comprehensive molecular profiling integrating genomic, epigenomic, and transcriptomic insights to measure response, resistance, and expression.
• Globally Harmonized Solutions – Harmonized assays to support clinical trials and commercialization in the US, JP, EU China.
Let’s connect and discuss how we can drive precision oncology forward together!
On Day 2 of ASCO-GU, Predicine proudly announce three urine-based ctDNA studies in urothelial carcinoma (UC):
Today’s Highlights:
• ctDNA genomic profiling using PredicineCARE™, improving clinical staging for upper tract urothelial carcinoma (UTUC).
• Methylation tumor fraction study using PredicineEPIC™, enabling early detection and recurrence monitoring of UC, with an AUC of 0.96.
• utDNA fragmentomic study using PredicineSCORE™ for improved UC diagnosis.
• Comprehensive molecular profiling using PredicineCOMPLETE™, integrating genomic, epigenomic, and transcriptomic profiling. (poster H24 by Tan from Vanderbilt>
Stop by Predicine Booth #56 or schedule a meeting MeetingASCOGU2025@predicine.com/" rel="ugc" target="_blank">https://outlook.office365.com/book/MeetingASCOGU2025@predicine.com/ to explore Predicine’s liquid biopsy solutions in clinical trial and patient testing.
13/02/2025
Stop by Predicine Booth #56 on Day 1 of ASCO-GU and explore our latest publications on liquid biopsy in mCRPC.
Discover the power of Predicine’s cutting-edge liquid biopsy solutions in metastatic castration-resistant prostate cancer (mCRPC).
Highlights:
• 43% of mCRPC patients received on-label treatment recommendations through comprehensive testing.
• PredicineCARE™ cfDNA alone identified 68% of actionable cases, reducing reliance on tissue biopsies.
• Repeat cfDNA testing uncovered 28% more patients with treatment recommendations.
to explore how our global network of labs and decentralized CDx and kit manufacturing is advancing clinical trials, biomarker discovery, and CDx development worldwide.
08/02/2025
Predicine Liquid Biopsy Summit 2025 - Shanghai
We're excited for the upcoming Predicine Liquid Biopsy Summit 2025 - Shanghai on February 9, 2025. 👏 Join us for an insightful event featuring industry and clinical experts in liquid biopsy and precision oncology.
Event Highlights:
• Baseline-informed personalized MRD vs. tumor-agnostic MRD
• Blood and urine-based ctDNA studies for treatment selection, monitoring, and resistance MOA
• Predicine’s globally harmonized liquid biopsy solutions for clinical trials, CDx development, and commercialization
We’re looking forward to ASCO GU 2025 in San Francisco and hope to see you there.
Don’t miss 5 studies utilizing Predicine’s blood- and urine-based liquid biopsy solutions for treatment selection, MRD, and comprehensive molecular profiling integrating genomics, epigenomics and transcriptomics.
Meet with Predicine at Predicine Booth #56 and register for the Annual Predicine ASCO GU Networking Reception on Thursday evening February 13th. Register HERE: mailchi.mp/c8c00e847ba9/predicine-asco-gu-2023-poster-preview-17991304?e=__test_email__
Schedule a meeting: Connect with our experts to discuss collaboration opportunities in clinical trials, CDx and commercialization: Schedule Here: outlook.office365.com/book/MeetingASCOGU2025@predicine.com/
Be the first to know and let us send you an email when Predicine posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.
Empower the global healthcare ecosystem through innovation
Who we are
Our founders are international experts in cancer research and drug development. Educated and trained in both China and the United States, we are enthusiastically devoted to address the rising and urgent healthcare needs in today's global drug development.
The makeup of Predicine is a group of industry veterans with hands-on experience, broad knowledge, and domain expertise in non-invasive diagnostics, cancer immunotherapy, clinical drug development, diagnostic assay development, next-generation sequencing, bioinformatics, big data analysis, and cloud computing
What we do
In order to address the challenge, Predicine was founded to develop precision diagnostics and medicine development platform to enable personalized cancer care and drug development through scientific and technological innovation, collaboration and partnership. Following the principles of science-driven and patient-first spirit, Predicine aims to develop and bring the first- and best-in-class precision medicine portfolio to address the unmet medical needs in global drug development.
Predicine develops innovative precision diagnostic products in cancer and other devastating diseases, establishes an integrated "one-stop-shop" biomarker service platform, and conducts big data analyses to enable precision medicine in personalized cancer care and global drug development.
Predicine operates in Hayward, California, USA and Shanghai, China.
